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Abstract
 
CD8
 

 
 cytotoxic T lymphocytes (CTLs) play an important role in containment of virus replication
in primary human immunodeficiency virus (HIV) infection. HIV’s ability to mutate to escape
from CTL pressure is increasingly recognized; but comprehensive studies of escape from the
CD8 T cell response in primary HIV infection are currently lacking. Here, we have fully char-
acterized the primary CTL response to autologous virus Env, Gag, and Tat proteins in three
patients, and investigated the extent, kinetics, and mechanisms of viral escape from epitope-
specific components of the response. In all three individuals, we observed variation beginning
within weeks of infection at epitope-containing sites in the viral quasispecies, which conferred
escape by mechanisms including altered peptide presentation/recognition and altered antigen
processing. The number of epitope-containing regions exhibiting evidence of early CTL escape
ranged from 1 out of 21 in a subject who controlled viral replication effectively to 5 out of 7 in
a subject who did not. Evaluation of the extent and kinetics of HIV-1 escape from 
 

 
40 differ-
ent epitope-specific CD8 T cell responses enabled analysis of factors determining escape and
suggested that escape is restricted by costs to intrinsic viral fitness and by broad, codominant
distribution of CTL-mediated pressure on viral replication.
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Introduction
 
HIV-1–specific CD8
 

 
 CTL responses are induced in pri-
mary infection (1, 2) and multiple lines of evidence suggest
that they make an important contribution to control of
acute and early viral replication (for review see reference
3). Prophylactic and therapeutic vaccination strategies are
being designed to target this arm of the immune response;
however, there are several factors that may limit their
success (4). Among these is viral sequence variation leading
to immune escape (5, 6). A better understanding of the
mechanisms by which HIV-1 evades control by the pri-
mary CTL response may thus help to facilitate rational
vaccine design.
Both we and others have demonstrated selection for viral
variants able to escape control by epitope-specific CTL re-
sponses during acute and early HIV-1 infection (7, 8);
however, problems associated with studying T cell re-
sponses in natural acute HIV-1 infection, including limited
availability of suitable samples and the sequence variability
among infecting virus strains, have made it difficult to gen-
eralize these findings, leaving many important questions
unanswered. CTL escape has been shown to be a hallmark
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of acute/early simian immunodeficiency virus infection (9).
Is it also typical of acute HIV infection? To what extent
and with what kinetics are epitope-specific responses
evaded, and what are the factors that control this? And how
do the primary CTL response and associated viral escape
relate to the persisting viral load established?
To begin to address these questions, we analyzed the
epitope specificity, breadth, and pattern of immunodomi-
nance within the primary CTL response to autologous vi-
rus Env, Gag, and Tat proteins in addition to the extent,
kinetics, and pathways of virus escape during acute and
early HIV-1 infection in three patients representative of
groups establishing persisting viral loads in the highest and
lowest ranges (10). In all three patients, we observed very
rapid escape from components of the primary HIV-specific
CD8 T cell response, demonstrating the potency of CTL
pressure on viral replication. However, there were marked
differences in the subsequent extent and kinetics of escape
in these individuals. By analyzing features of epitope-spe-
cific CD8 T cell responses escaped to differing extents/
with differing kinetics, we were able to gain insight into
the interacting factors that determine CTL escape, provid-
ing evidence that escape is restricted by viral fitness con-
straints and is promoted when a response makes a particu-
larly dominant contribution to control of viral replication
(due to its magnitude and/or efficacy). These results have
implications for HIV vaccine design, supporting the impor-
tance of restriction of viral escape from CD8 T cell control
and suggesting means by which this may be achieved.
 
Materials and Methods
 
Patient Samples.
 
All patients presented to hospital emergency
rooms affiliated with the University of Alabama at Birmingham
and were studied, with written informed consent, according to
protocols approved by the University’s Institutional Review
Board. The clinical profiles and viral loads of the three study sub-
jects have been reported previously: WEAU and BORI are pa-
tients 1 and 3, respectively (11), and SUMA is patient 4 (12);
additional viral load data has been described previously (13). Pe-
ripheral blood samples were collected in acid citrate dextrose.
PBMCs were isolated and cryopreserved as described previously
(1); plasma was also cryopreserved.
 
Recombinant Vaccinia Viruses (rVVs).
 
rVV vSC8, which ex-
presses only 
 
Escherichia coli
 
 
 

 
-galactosidase (
 

 
-gal) was obtained
from B. Moss (National Institutes of Health, Bethesda, MD).
rVVs coexpressing 
 

 
-gal and full-length gp160 or Gag proteins or
sections thereof derived from the autologous HIV-1 in patient
BORI at 9 days following onset of symptoms (DFOSx), and vi-
ruses expressing the Tat protein from patient SUMA’s autologous
virus at 8 or 69 DFOSx were produced by homologous recombi-
nation into the thymidine kinase gene of VV strain WR as de-
scribed previously (7). Protein expression was confirmed by West-
ern blotting.
 
Peptides.
 
Synthetic peptides were purchased as Pepsets pro-
duced in a peptide–amino acid format (Mimotopes) or were syn-
thesized by the protein chemistry unit (Institute for Animal
Health) using Fmoc or TBoc chemistry.
 
IFN-
 

 
 ELISPOT Assays.
 
IFN-
 

 
 ELISPOT assays were per-
formed as described previously (14). In brief, MultiScreen plates
(MAHA S45; Millipore) were coated overnight with anti–IFN-
 

 
capture antibody 1-D1K (5 
 

 
g/ml; Mabtech), washed four times,
and blocked. Patient PBMCs were added at 10
 
5
 
–2 
 

 
 10
 
5
 
 cells/
well and incubated for 18 h with peptides (at 10
 

 
5
 
 M) or 10 
 

 
g/
ml phytohaemagglutinin (Sigma-Aldrich) as a positive control.
Duplicate wells in which cells were incubated with medium only
were included on each plate as a negative control. Plates were
washed again, and IFN-
 

 
 spots were detected using 1 
 

 
g/ml bi-
otin-conjugated anti–IFN-
 

 
 mAb clone 7-B6-1 (Mabtech), 1
 

 
g/ml anti-biotin–ALP (Vector Laboratories), and a chromo-
genic alkaline phosphatase substrate (Bio-Rad Laboratories).
Spots were enumerated using an AID automated image analysis
system with AID ELISPOT version 2.5 software (Autoimmun
Diagnostika GmbH). Results are expressed as mean (of duplicate
or triplicate wells) spot-forming cells per 10
 
6
 
 PBMCs. In epitope
mapping experiments, responses were considered positive if they
exceeded the background counts (spots formed after stimulation
of PBMCs with medium alone) by 
 

 
50 spot-forming cells/10
 
6
 
PBMCs. All positive responses were confirmed in a minimum of
three independent experiments.
 
51
 
Cr Release Assays.
 
51
 
Cr release assays were performed as de-
scribed previously (7). Target cells were autologous or allogeneic
EBV-B-LCL, either infected 
 

 
18 h before the assay with rVVs (at
a multiplicity of infection of 10 PFU/cell) or left uninfected and
pulsed with synthetic peptides during the assay. rVV infection of
target cells was confirmed by fluorescein di-
 

 
-
 
d
 
-galactopyranoside
(FDG; BDH Laboratory Supplies) staining for 
 

 
-gal expression as
described previously (15). Target cells were used at 1.5 
 

 
 10
 
4
 
cells/well. Effector cells were either polyclonal CTL, produced by
culturing patient PBMCs for 10 d with 10 U/ml IL-2 (Glaxo
SmithKline) and anti-CD3 antibody (produced from hybridoma
OKT3) or short-term CTL lines generated by limiting dilution
culture. These were used at effector:target ratios of at least 50:1 for
polyclonal CTLs or 5:1 for lines. All variables were assayed in trip-
licate. Results are expressed as the percent specific 
 
51
 
Cr release, cal-
culated (as mean test counts 
 

 
 mean spontaneous counts/mean
maximum counts 
 

 
 mean spontaneous counts) 
 

 
 100.
 
Viral Sequencing.
 
Gp160, Gag, and Tat genes were amplified
by nested PCR from plasma HIV-1 RNA and sequenced. In
brief, HIV-1 RNA was isolated from virions in plasma using a
QIAmp Viral RNA Mini Kit (QIAGEN), and cDNA was pre-
pared from replicate plasma virus RNA preparations (4,000–
8,000 RNA molecules/reaction) using SuperScript II (Invitro-
gen). Replicate cDNA samples (1, 10, 100, or 1,000 molecules
each) were subjected to nested PCR amplification as described
previously (7), using primer sequences listed in Table S1 (avail-
able at http://www.jem.org/cgi/content/full/jem.20040511/DC1).
The PCR products were cloned into pCR-XL-TOPO (Invitro-
gen), and double-strand sequence analysis was performed using
an ABI 373A Sequenator and the Taq Dye Primer Cycle Se-
quencing Kit (ABI). The sequences were analyzed using Se-
quencher (Gene Codes Corp) and Microgenie (Beckman Coulter)
software packages.
 
Online Supplemental Material
 
Fig. S1 shows computer-gener-
ated models of index HIV-1 epitope peptides and variants thereof
bound to their restricting HLA class I molecules. Table S1 depicts
primers used for nested PCR amplification of HIV-1 genes from
plasma viral RNA. Table S2 shows the number of CD8 T cells
producing IFN-
 

 
 in response to stimulation with epitope pep-
tides at time points in acute, subacute, and early infection in pa-
tients BORI, WEAU, and SUMA. Online supplemental ma-
terial is available at http://www.jem.org/cgi/content/full/
jem.20040511/DC1.
 Jones et al.
 
1245
 
Results
 
Characterization of the Primary CD8
 

 
 T Cell Response
to Autologous Virus Env, Gag, and Tat Proteins.
 
Subjects
WEAU, BORI, and SUMA each presented with acute
symptomatic HIV-1 infection, with high titres of circulating
virus and undetectable HIV-1 antibodies (11, 12). None of
these patients received early antiretroviral therapy. After
clinical resolution of primary HIV infection, WEAU and
BORI established high persisting viral loads (90,109 HIV-1
RNA copies/ml at 212 d after onset of symptoms [DFOSx]
and 186,305 HIV-1 RNA copies/ml at 218 DFOSx, re-
spectively) and both experienced marked declines in periph-
eral blood CD4 cells within 2 yr of infection (to 30 and 393
Figure 1. Relative immuno-
dominance and functional avidity
of T cell responses to different
viral epitopes during acute, sub-
acute, and early HIV-1 infection
in subjects BORI, WEAU, and
SUMA. The T cell response to
each of the gp160, Gag, and Tat
epitopes recognized by subjects
BORI, WEAU, and SUMA was
measured at time points during
acute HIV-1 infection (9–16
DFOSx and before detection of
HIV-1 antibodies by ELISA or
Western immunoblot), subacute
infection (3–4 wk FOSx and be-
fore full immunoblot seroconver-
sion), and early infection (between
5 and 10 wk FOSx) using IFN-
ELISPOT assays. The relative
immunodominance of the re-
sponses to different epitope pep-
tides at each time point is shown,
calculated by expressing the num-
ber of epitope–peptide-specific
IFN-–producing cells as a per-
centage of the overall response
detected to all the peptides tested
at that time point. The magnitude
of individual epitope-specific re-
sponses is shown in Table S2.
The functional avidity of patient
T cell responses to each of the
epitopes they recognized was
also compared by assessing the
ability of polyclonal patient CTL
or epitope-specific CTL lines to
mediate lysis of autologous EBV-
B-LCL target cells pulsed with
different concentrations of the
epitope peptide in 51Cr release
assays. The values shown repre-
sent the peptide concentration
required to sensitize target cells
for half-maximal CTL lysis.
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Table I.
 
Epitopes/Epitope-containing Regions Identified as Being Recognized by the CD8
 

 
 T Cell Response during Acute/Early HIV-1 
Infection in Subjects BORI, WEAU, and SUMA
 
Patient Viral protein Epitope/region
 
a
 
Designation MHC restriction
 
b
 
BORI gp160 207-
 
S
 
FE
 
PI
 
PIH
 
Y
 
-215 gp160 SY9 A
 
*
 
2902
gp160 237-CK
 
NV
 
S
 
TVQ
 
C-245 gp160 CC9 C
 
*
 
0802
gp160 589-
 
ER
 
YLKDQ
 
Q
 
L-597 gp160 EL9 B
 
*
 
1402
Gag 119-
 
AA
 
D
 
TGN
 
SS
 
Q
 
-127 Gag AQ9 ND
Gag 124-
 
N
 
SS
 
Q
 
V
 
S
 
Q
 
NYP-133 Gag NP10 ND
Gag 295-DRFY
 
K
 
TLR
 
A
 
EQ-305 Gag DQ11 B
 
*
 
1402
Gag 138–156 Gag 138–156 ND
Tat 24-NC
 
Y
 
CK
 
K
 
CCY-32 Tat NY9 A
 
*
 
2902
WEAU gp160 30-A
 
E
 
N
 
L
 
WVT
 
V
 
Y-38 gp160 AY9 B
 
*
 
4403
gp160 214-
 
S
 
FE
 
PI
 
PIH
 
Y
 
-222 gp160 SY9 A
 
*
 
2902
gp160 313-TL
 
G
 
P
 
G
 
R
 
V
 
L
 
Y
 
-321 gp160 TY9 ND
gp160 348–366 gp160 348–366 ND
gp160 828-
 
EGT
 
D
 
R
 
IV
 
I
 
EI-836 gp160 EI9 ND
gp160 837-V
 
QR
 
TC
 
RAIL-845 gp160 VL9 ND
Gag 71–90 Gag 71–90 ND
Gag 99-EVKDTKEAL-107 Gag EVL9 B*0801
Gag 153-NAWVKIEEK-162 Gag NK9 ND
Gag 175-LSEGATPQDL-184 Gag LL10 B*4403
Gag 231–270 Gag 231–270 ND
Gag 380–410 Gag 380–410 ND
Tat 24-NCYCKRCCF-32 Tat NF9 A*2902
Tat 80–101 Tat 80–101 ND
SUMA gp160 29-ENLWVTVYY-37 gp160 EY9 ND
gp160 160–180 gp160 160–180 ND
gp160 374-NCGGEFFYCN-383 gp160 NN10 ND
gp160 380-FYCNTTQLF-389 gp160 FF9 A*2402
gp160 390–401 gp160 390–401 ND
gp160 402–413 gp160 402–413 ND
gp160 410-425 gp160 410–425 ND
gp160 426-441 gp160 426–441 ND
gp160 439-IRCSSNITGL-448 gp160 IL10 ND
gp160 485-YKVVKIEPL-493 gp160 YL9 ND
gp160 583-ERYLKDQQL-591 gp160 EL9 B*1402
Gag 5-ASVLSGGEL-13 Gag AL9 ND
Gag 83-TLYCVHQKI-91 Gag TI9 A*1103
Gag 260-EIYKRWIIL-268 Gag EIL9 A*2402
Gag 269-GLNKIVRMY-277 Gag GY9 B*1501
Gag 295-DYVDRFYKT-303 Gag DT9 A*2402
Gag 305-RAEQASQEV-313 Gag RV9 C*0802
Gag 335-KALGPAATL-343 Gag KL9 ND
Gag 349-ACQGVGGPGHK-359 Gag AK11 A*1103
Gag 410-440 Gag 410–440 ND
Tat 12-KHPGSQPKTA-21 Tat KA10 ND
Tat 32-FHCQVCFMTK-41 Tat FK10 ND
Tat 36-VCFMTKGLGI-45 Tat VI10 B*1501
Tat 39-MTKGLGISY-47 Tat MY9 B*1501
aThe NH2- and COOH-terminal amino acid numbers of each epitope/epitope-containing region within the subject’s autologous virus Env, Gag,
or Tat protein sequence are shown. Where the optimal epitope sequence was determined, the amino acid sequence of the epitope (as present in the
subject’s autologous virus at the earliest time point analyzed) is also given. The residues within each optimal epitope sequence are coded to indicate
the extent of amino acid variability at that position amongst the HIV-1 clade B sequences listed in the HIV sequence database (reference 21). Resi-
dues shown in regular text were invariant amongst all sequences compared; at bold positions, there was very low variability, with 95% of se-
quences sharing a common amino acid; at italicized positions, there was more variability, with 	95 but 79% of sequences sharing a common
amino acid; and at underlined residues, there was greatest variability, with 
79% of sequences sharing a common amino acid. 
bThe HLA class I allele presenting each epitope is shown, where known. In some cases, the restriction of the epitope-specific response was deter-
mined experimentally, whereas in others the presenting HLA allele was deduced based on previous reports of the HLA restriction of the epitope
concerned (reference 46).
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cells/mm3, respectively). Conversely, SUMA established a
very low persisting viral load (2,268 HIV-1 RNA copies/ml
at 278 DFOSx) and maintained a high CD4 count (722
cells/mm3) throughout 7 yr of follow-up (13).
Initial analysis of the primary CTL response in these sub-
jects indicated that responses to Env, Gag, and/or Tat were
particularly immunodominant (reference 1 and unpublished
data); thus, we focused our analysis on these proteins. We
began by mapping the epitopes recognized by CD8 T cells
derived from each patient during the first 3 mo of infection.
To avoid missing T cell responses due to sequence differ-
ences between the patients’ autologous virus proteins and
heterologous reagents, epitope mapping was performed us-
ing reagents corresponding to the earliest available sequence
of each patient’s autologous virus (15, 9, and 4 DFOSx in
WEAU, BORI, and SUMA, respectively). In WEAU and
SUMA, epitopes were located by screening overlapping
synthetic peptides corresponding to their autologous viral
gp160, Gag (p24/p17), and Tat sequences, whereas in
BORI, epitope-containing regions in gp160 and Gag were
initially located by testing the recognition of rVVs express-
ing sections of the autologous virus gp160 and Gag se-
quences followed by more precise epitope mapping within
these regions and also in Tat using synthetic peptides.
The epitopes to which responses were identified in each
patient, together with their HLA restriction where charac-
terized, are shown in Table I. Responses to between 8 and
24 epitopes were identified in each patient, emphasizing
the potential breadth of the virus-specific CD8 T cell re-
sponse in primary HIV-1 infection (16). The HIV-specific
CD8 response in patient SUMA was directed against a
minimum of 24 epitopes in gp160, Gag, and Tat alone,
with limited analysis of the HLA restriction of these re-
sponses revealing usage of all four HLA-A and -B alleles,
and at least one HLA-C allele. Notably, the epitope
breadth of the CD8 T cell response to gp160, Gag, and
Tat in SUMA was almost twice that in WEAU, and more
than twice that identified in BORI. Furthermore, individ-
ual epitope-specific responses in patient SUMA also used a
broad array of T cell clones (unpublished data).
Next, we compared the relative magnitude of the T cell
response to the different epitopes each patient recognized
during acute (HIV-1 ELISA and immunoblot negative),
subacute (antibody indeterminant), and early (antibody pos-
itive) infection. This analysis (Fig. 1 and Table S2) revealed
marked differences in the relative immunodominance of
epitope-specific responses within the primary HIV-specific
CD8 T cell response in the three individuals. Most nota-
bly, in the two patients who subsequently established high
persisting HIV-1 loads, the virus-specific CD8 T cell re-
sponse during acute HIV-1 infection was highly biased to-
ward one (WEAU) or several (BORI) viral epitopes. Al-
though the response in these patients evolved after control
of the acute viral burst to become somewhat less heavily
weighted toward the initially immunodominant epitopes, it
still remained very unevenly biased: in WEAU, 90% of
the T cell response analyzed was directed against just five vi-
ral epitopes in early infection, and there was a similar pic-
ture in BORI. In contrast, although there was also a hierar-
chy of epitope immunodominance in SUMA’s primary
HIV-specific CD8 T cell response, with responses to two
epitopes (gp160 EL9 and Tat MY9) being particularly
prominent during acute infection, the CTL response rapidly
became more evenly balanced, so that in early infection,
only 20% of the response was directed toward these
epitopes and 80% was spread over the remaining epitopes.
The avidity of the T cell response to certain of the
epitopes recognized in each patient was also evaluated (Fig.
1). Analysis of the relationship between the avidity and im-
munodominance of T cell responses to different epitopes
during acute and early infection revealed that the most im-
munodominant responses in all three patients were fre-
quently of moderate-to-high avidity (107/8 M), although
there was not a significant correlation between avidity and
immunodominance.
Analysis of Selection for Sequence Changes within CTL
Epitope-containing Regions. Next, we investigated the ex-
tent, kinetics, and mechanisms of viral escape from each of
the epitope-specific CD8 T cell responses identified in the
three study subjects. Direct population sequencing of gag,
env, and tat genes from uncultured plasma virus RNA
(cDNA) from serial time points was performed, as described
previously (7, 17). The same genes were molecularly cloned
from plasma viral RNA (cDNA) and individual clones were
sequenced. Both approaches were used to identify changes
in the plasma virus quasispecies of the three subjects over the
course of 556–772 d of follow-up. Particular attention was
given to sequences encompassing the epitopes shown to be
recognized by each patient’s CTL response. In all, 298 com-
plete genes and 1,044 subgenomic fragments, together total-
ling 840,000 nucleotides, were analyzed (GenBank/EMBL/
DDBJ accession nos. AY281863-AY282367, AY223719-
AY223754, AY223761-AY223790, and U21135). Changes
that emerged within stretches of sequence containing one or
more CTL epitopes (epitope-containing regions) are shown
in Fig. 2. Complete replacement of the initial (highly homo-
geneous) virus population with viruses bearing nonsynony-
mous sequence changes within one or more epitope-con-
taining regions was found to occur with very rapid kinetics
in all three patients (Fig. 2). In BORI and WEAU, there was
rapid selection for amino acid changes in multiple epitope-
containing regions (6 out of 7 in BORI and 4 out of 14 in
WEAU) within the first year of infection. Conversely, of the
24 epitopes recognized by SUMA, there were changes dur-
ing the same time frame in only a single region of Tat that
was targeted by CTL responses against three overlapping
CTL epitopes. Only much later, at 736 DFOSx, were
changes detected in a fourth epitope in the env gene.
Effects of Amino Acid Changes Selected In Vivo on Epitope
Recognition or Processing. Next, we examined the pheno-
typic effects of these changes on virus susceptibility to CTL
recognition. First, the ability of synthetic peptides corre-
sponding to the index and variant sequences of each vari-
able epitope to sensitize autologous target cells for lysis by
polyclonal patient CTLs was evaluated. In the vast majority
of instances where the frequency of epitope-specific CTLs
Determinants of HIV Escape from Cytotoxic T Cells1248
was high enough to permit this analysis, the amino acid
changes that were selected for within epitope sequences
were found to reduce the ability of the epitope peptide to
sensitize target cells for CTL lysis by at least 10-fold, and in
some cases to undetectable levels (Fig. 3). We did not in-
vestigate directly whether this was due to impairment of
peptide binding to MHC and/or to alteration of recogni-
tion of the peptide–MHC complex by T cells after binding
to MHC. However, computer-generated peptide–MHC
models of the index and predominant mutant forms of
epitope peptides whose HLA restriction was known (Fig.
S1, available at http://www.jem.org/cgi/content/full/jem.
Figure 2. Summary of sequence changes detected
over time in each subject’s plasma virus quasispecies
within regions recognized by the CD8 T cell re-
sponse. Sequence changes occurring within epitope-
containing regions in the in vivo viral quasispecies
over time in (a) BORI, (b) WEAU, and (c) SUMA
are shown. A panel of molecular clones spanning
each epitope-containing region was derived from
plasma viral RNA (cDNA) at serial time points in
infection (DFOSx), and the sequence of indepen-
dent clones was determined. Each panel shows the
deduced amino acid sequence of clones from a
single epitope/epitope-containing region. Where
overlapping CD8 T cell epitopes were identified
within one region, their relative location is indi-
cated. For each epitope/epitope-containing region,
the deduced amino acid sequence of the predomi-
nant viral species present at the earliest time point
tested (the index sequence) is shown in full. Any
variant sequences present at this time point, plus all
sequences determined at subsequent time points
were compared with the index sequence; variant
amino acids are indicated, with a dash (-) denoting
amino acid identity. The slash (/) denotes an amino
acid deletion, and insertions are indicated by vertical
pipes. At each time point, the proportion of clones
analyzed that had a given sequence is shown, and
the total percentage of clones analyzed with variant
sequences is also indicated. Sequence analysis of the
WEAU gp160 AY9 epitope at time points from D16
to D136 was reported previously (reference 7).
Jones et al.1249
20040511/DC1) suggested that in the majority of cases
(7/8 examples analyzed), the amino acids that were altered
did not form part of the TCR contact surface. Conversely,
alterations in MHC anchor residues (e.g., positions 2, 3,
and/or 9 of the HLA-A29–restricted epitope SFEPIPIHY;
position 5 of the HLA-B14–restricted epitope ERYLKDQQL;
and position 2 of the HLA-B44–restricted epitope AENL-
WVTVY) were relatively common.
Although in the majority of cases tested, the amino acid
changes selected for within epitope sequences reduced the
Figure 2 continued.
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ability of the epitope peptide to sensitize target cells for lysis
in vitro, one of the exceptions to this was the position 2
threonine (T) to lysine (K) change in the Tat MY9 epitope
in patient SUMA (Fig. 3 c). The region of Tat where this
epitope was located also contained two other overlapping
CTL epitopes (Fig. 2 c), whose recognition was ablated by
the amino acid changes selected for in this region. Al-
though the T cell response to the latter epitopes may have
driven the emergence of these amino acid changes, this
seemed unlikely given that these responses were not at all
dominant in the patient’s primary CD8 T cell response
and were of very low avidity (Fig. 1). This suggested that
Figure 3. Effect of the amino acid
changes selected for in each subject’s in vivo
viral quasispecies on epitope-specific CD8
CTL responses. The relative ability of syn-
thetic peptides corresponding to the indi-
cated index and variant epitope sequences
to sensitize autologous target cell lines for
lysis by polyclonal CTLs derived from sub-
jects BORI (a), WEAU (b), and SUMA (c)
early after infection was compared using in
vitro cytotoxicity assays. The results shown
are the specific lysis (% specific 51Cr release)
of target cells incubated with the indicated
concentrations of each peptide.
Jones et al.1251
the amino acid changes that emerged in this region of Tat
may have been selected for because they conferred escape
from the Tat MY9 response by affecting the processing of
this epitope. To investigate this possibility, we generated
two rVVs encoding the index (D8) and variant (D69) pa-
tient virus Tat sequences (which differed only in the F to L
and T to K substitutions at positions 32 and 40), and com-
pared their ability to sensitize autologous target cells for ly-
sis by a CTL line specific for the Tat MY9 epitope. Both
viruses expressed similar levels of Tat (Fig. 4 a) and infected
target cells with high efficiency (Fig. 4 b); but only the vi-
rus expressing the index Tat sequence sensitized target cells
for lysis by Tat MY9-specific CTLs (Fig. 4 c). Together
with the observation that the mutant Tat MY9 epitope
peptide was able to sensitize target cells for CTL lysis just as
efficiently as the index peptide (Fig. 3 c), this result sug-
gested that the amino acid changes at Tat residues 32 and/
or 40 in the D69 Tat sequence prevented processing of the
Tat MY9 epitope for presentation with HLA-B15. Other
instances of HIV-1 escape from epitope-specific CD8 re-
sponses via acquisition of mutations affecting antigen pro-
cessing have been reported recently (18).
A notable example of selection for amino acid change in
an epitope-containing region to which a subdominant CTL
response was mounted was at gp160 348–366 in WEAU.
Sequence analysis of this region (Fig. 2) suggested selection
pressure beginning as early as day 44, with fixation of a
lysine (K) to glutamic acid (E) substitution by day 136. CTL
reactivity to this region was too low to enable the effects of
this mutation on the CTL response to be investigated, but
in other studies involving the same subject, we found that
this K to E substitution contributed to virus escape from au-
tologous neutralizing antibodies (NAbs; reference 19).
Altogether, six out of eight epitopes in BORI had
changes consistent with CTL escape, of which changes in
five (gp160 SY9, gp160 EL9, Gag AQ9, Gag NP10, and
Tat NY9) were confirmed to affect CTL recognition (Fig. 3
a), with a sixth not tested. In WEAU, changes in 4 out of
14 epitopes suggested possible CTL escape with 2 (gp160
AY9 and gp160 SY9) confirmed as such (Fig. 3 b). A third
(Tat NF9) likely also represented escape by analogy with es-
cape at the same Tat epitope in BORI (Fig. 3 a). In SUMA,
changes in 4 out of 24 epitopes, 3 of which were overlap-
ping, all suggested escape. Three were confirmed as such
(Figs. 3 c and 4), and the fourth (gp160 EL9) was suggested
by analogy with escape at the same gp160 epitope in BORI.
Features of Epitope-specific Responses Associated with Selection
for Escape Mutations. In total, 14 out of the 46 CTL re-
sponses studied here were associated with evolution of viral
sequence changes suggesting possible CTL escape. Escape
from responses directed against certain epitopes may be re-
stricted by the costs of mutation to viral fitness (see next
Figure 4. Effect of amino acid
changes selected for in SUMA’s
Tat sequence on processing of
the Tat MY9 epitope. (a) Con-
firmation of Tat expression in
cells infected with rVVs encod-
ing Tat proteins cloned from the
plasma viral population present
in SUMA 8 (vSUMAtat-D8) or
69 (vSUMAtat-D69) DFOSx.
Western blotting was performed
on lysates from cells infected 48 h
previously with vSC8 (a con-
trol rVV expressing -gal only),
vSUMAtat-D8, or vSUMAtat-
D69, using the HIV-1 Tat-specific
monoclonal antibody EVA3021.
The positions of molecular
weight markers (daltons) are
shown, and the Tat band is indi-
cated by an arrow. (b) Confirma-
tion of efficient infection of target
cells by vSC8, vSUMAtat-D8,
and vSUMAtat-D69. EBV-B-
LCL target cells were infected at
an multiplicity of infection of 10
with the indicated rVVs (all of
which expressed the marker pro-
tein -gal), and the proportion
of infected cells was assessed 18 h
later by staining with FDG, a
fluorescent substrate for -gal.
Unshaded histograms represent
FDG staining of uninfected cells, and shaded histograms represent staining of infected cells. (c) Analysis of the ability of a Tat MY9-specific CTL line
derived from subject SUMA early after infection to mediate lysis (% specific 51Cr release) of autologous (auto) and allogeneic (allo) EBV-B-LCL target
cells infected with vSC8, vSUMAtat-D8, or vSUMAtat-D69, or pulsed with the MY9 epitope peptide at 105 M.
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paragraph). Nonetheless, comparison of features of re-
sponses that were differentially escaped suggested that both
quantitative and qualitative factors play a role in determin-
ing the pressure exerted by individual epitope-specific CTL
responses on in vivo viral replication. The responses that
were of highest magnitude during acute infection in each
patient were among those that were escaped; but there was
also evidence of rapid escape from relatively subdominant
responses. Although many immunodominant responses
were of high functional avidity (Fig. 1), there was not
strong evidence to support functional avidity being an im-
portant independent determinant of CTL escape. How-
ever, the protein specificity of responses did seem to play a
role, as 5/7 (71%) responses to epitopes in Tat, a protein
expressed early in the viral lifecycle, were escaped, whereas
only 10/39 (26%) responses directed against gp160 and Gag
were escaped in a similar time frame, a significantly lower
proportion (P  0.026 as determined using Fisher’s exact
test). A recent in vitro paper lends further support to speci-
ficity being more important than avidity in determining the
antiviral efficacy of CTL (20).
Constraints on Viral Sequence Variability Restrict CTL Es-
cape. To investigate the impact of sequence constraints
imposed by the need to maintain viral replicative functions,
we compared the extent and kinetics of escape from CTL
responses directed against epitopes located in conserved and
more variable viral sequences. In Table I, the epitope se-
quences are coded to reflect the degree of conservation of
each amino acid among clade B HIV-1 sequences (21).
Some of the most highly conserved epitope sequences were
those in Gag p24, including the HLA-B14–restricted Gag
DQ11 epitope recognized by patient BORI, where con-
straints on immune escape due to the essential role of in-
variant amino acids have been reported previously (22). No
escape from responses to these highly conserved Gag p24
epitopes was observed. Certain gp160 epitopes were also
relatively conserved, such as the HLA-A29–restricted gp160
SY9 epitope recognized by BORI and WEAU and the
B14-restricted gp160 EL9 epitope recognized by BORI
and SUMA. There was slow selection for amino acid
changes that conferred some resistance to recognition by
the T cell response directed against these epitopes; but
these changes did not ablate epitope recognition altogether
(Fig. 3), likely reflecting constraints on the positions within
the epitope at which even conservative amino acid changes
could be tolerated (e.g., possibly just at position 5 in the
gp160 EL9 epitope). In contrast, other epitopes, such as the
overlapping Gag p17 epitopes (Gag AQ9 and Gag NP10)
recognized by patient BORI, were located in more vari-
able sequences where rapid acquisition of amino acid
changes that conferred a high degree of CTL escape could
likely be accommodated more readily.
Comparison of the Overall Extent and Kinetics of Escape from
the Primary HIV-specific CTL Response in Patients BORI,
WEAU, and SUMA. The overall extent and kinetics of
virus escape from epitope-specific CTL responses in each
subject are illustrated in Fig. 5. In every case, there was ev-
idence for complete or near-complete fixation of escape
mutants in at least one CTL epitope within 65–72 DFOSx.
However, in BORI and WEAU, there was evidence of se-
quential fixation of multiple escape mutations within the
first 1 yr of infection (Fig. 5, a and b). Conversely, there
was much more limited CTL escape in SUMA during the
same time frame (Fig. 5 c). To confirm the validity of the
latter observation (and exclude the possibility that there was
extensive escape from responses directed against epitopes in
other viral proteins during early infection in patient
SUMA), we have recently extended similar analysis to
SUMA’s primary CD8 T cell response against the entire
autologous virus proteome. This revealed that there was no
selection for escape-conferring amino acid changes within
or around any other epitopes in the virus throughout the
first year of infection (unpublished data).
The limited early viral mutational escape in patient
SUMA ensued in the context of a CD8 T cell response that
was broad and relatively evenly directed. In contrast, in pa-
tients BORI and WEAU, the primary CTL response was
more heavily biased against a limited number of viral
epitopes. This suggests the importance of broad, even dis-
tribution of CD8 T cell pressure in restricting viral escape,
a hypothesis further supported by observation that the re-
sponse to an epitope (gp160 EL9) that was recognized by
both BORI and SUMA was escaped more rapidly in the
former patient, where it formed part of a relatively unbal-
anced CTL response, than in the latter patient where it
formed part of a broader, more evenly directed response
(Fig. 5, d–g).
Discussion
Understanding the dynamic virus–immune system inter-
actions that take place during acute HIV-1 infection and
how they may impact on the persisting viral load is impor-
tant but technically challenging. In this paper, we charac-
terized the primary CD8 T cell response to autologous
virus Env, Gag, and Tat proteins (which together com-
promise 45% of the viral proteome) and escape from
this response in three HIV-1–infected individuals. We ob-
served rapid escape from components of the primary HIV-
specific CTL response in all three subjects, but found a
marked difference in the subsequent extent and kinetics of
escape in these individuals. By analyzing quantitative and
qualitative features of CD8 T cell responses directed against
40 different epitopes and their escape from CTL control,
we were able to gain insight into the interacting factors that
determine CTL escape. Our results suggest that costs to in-
trinsic viral fitness and broad, codominant distribution of
CTL-mediated pressure on viral replication restrict escape
and imply that this may in turn influence the extent to
which virus containment is achieved.
In all three of our study subjects, there was complete or
near-complete replacement of the replicating viral quasi-
species by mutants able to escape from components of the
primary CTL response within 65–72 DFOSx, demonstrat-
ing the controlling pressure exerted by CD8 T cells on
HIV replication during primary infection. In contrast, au-
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tologous HIV-1 NAbs were not detectable in the same
subjects until 72 DFOSx or later, and NAb escape mutants
were generally not found until later still (19). These and
other results (1–3, 7, 23) emphasize the difference in kinet-
ics of the CD8 T cell and NAb responses in primary HIV-1
infection, and clarify that the virus-specific CD8 T cell
response plays the dominant role in containing virus repli-
cation in the earliest stages of natural infection.
From the kinetics of replacement of wild-type virus in
the plasma by escape mutants, we could calculate the selec-
tive advantage that escape from epitope-specific responses
conferred on the virus, and hence gain a minimum estimate
of the impact of the CTL response on viral replication.
Based on frequency estimates of single point mutations of
102–104 (24) (compatible with the reported HIV muta-
tion rate of 3.4  105 mutations per base pair per single
cycle of replication; reference 25), a virus generation time of
2 d (26), and our observation that the earliest escape-con-
ferring mutations reached fixation in the plasma viral popu-
lation within 60–80 d, we calculated (24) the relative fitness
advantage of mutant viruses over wild-type virus (in the face
of CTL pressure) to be 1.12–1.36. Thus, individual epi-
tope-specific CTL responses reduced viral replication by
at least 10–30%; i.e., if a cell infected with wild-type virus
has the capacity to produce 100 infectious virions in its life-
time (burst size), a CTL response to only a single epitope
would reduce the burst size to between 70 and 90 infectious
virions. We have shown previously how modest reductions
in the lifespan of productively infected cells could elicit such
an effect on virus burst size, and by inference, on plasma vi-
rus load (27, 28). Notably, the CTL responses that drove
complete selection for escape-conferring mutations most
rapidly were directed against epitopes in Tat (the Tat NY9
response in BORI and the Tat MY9 response in SUMA,
which were escaped to completion within 65/69 DFOSx,
respectively). There is also other evidence for responses to
Tat (and Nef and Rev) being particularly effective at con-
trolling in vivo virus replication (9, 29, 30). These proteins
are all expressed early in the viral life cycle, allowing rapid
epitope presentation on infected cells and providing a
longer “window of opportunity” for CTL action, which in
vitro studies have shown can considerably enhance the effi-
ciency of CTL control of viral replication (20, 31).
Although components of the primary HIV-specific CTL
response were initially escaped with similar kinetics in all
three subjects, there was a marked difference in the subse-
quent extent and kinetics of CTL escape in these individu-
als. In both BORI and WEAU, there was selection for mu-
tations in multiple (four to six) epitope-containing regions
within 218 DFOSx, whereas in SUMA there was acute
phase escape in just a single epitope-containing region in
the entire virus, and no further CTL escape until much
later into infection (Fig. 5). In all three subjects, CTL es-
cape occurred as primary virus replication was being con-
tained. Given that the escape-conferring mutations must
have conferred a fitness advantage on the virus to have been
selected for in the in vivo viral quasispecies, escape variant
selection must, by definition, have affected the efficiency of
Figure 5. Extent and kinetics of escape-conferring
mutation in epitope-containing regions in Env, Gag,
and Tat in subjects BORI, WEAU, and SUMA. Panels
a and e; b; and c illustrate (for subjects BORI, WEAU,
and SUMA, respectively) the extent and kinetics of accu-
mulation of mutations (with the exception of those
shown not to confer CTL escape in Fig. 3) within
epitope-containing regions in gp160, Gag, and Tat (%
mutant) at time points analyzed during the first 400
DFOSx. In BORI, the five mutating regions shown
constituted five out of seven epitope-containing regions
identified in this patient; in WEAU, the 4 mutating
epitope-containing regions constituted 4 of 14 regions
to which responses were identified, and in SUMA the
single mutating epitope-containing region (which con-
tained the Tat FK10/VI10/MY9 epitopes) constituted
1 of 21 regions to which responses were identified.
Panels d and f show the relative immunodominance
(calculated as described in the legend to Fig. 1) of the
response to the gp160 EL9 epitope in subjects BORI
and SUMA respectively. Panels e and g illustrate the
kinetics of accumulation of escape-conferring mutations
(% mutant) in this epitope within the viral quasispecies in
subjects BORI and SUMA, respectively.
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control of virus replication. It is notable that SUMA, whose
virus underwent very limited escape from the primary CD8
T cell response, established a low set-point persisting viral
load, whereas the other two patients, in whom there was
much more extensive escape during the first 6 mo of infec-
tion, established high persisting viral loads. These observa-
tions are consistent with the hypothesis that the extent of
acute-phase viral escape from the CD8 T cell response may
be one of the factors that determines the persisting viral
load established in early HIV-1 infection. In turn, the level
of viral replication may impact on the kinetics of escape vi-
ral variant selection. However, the multiple observations
(32) of rapid viral evolution to acquire resistance to antiret-
roviral agents in patients where the level of ongoing viral
replication had been reduced to levels much lower than
that in patient SUMA would argue against the viral load
being the key factor limiting escape in this patient.
The differing levels of escape in these three patients oc-
curred in the context of CTL responses that differed in
both epitope breadth and in the relative immunodomi-
nance of responses to individual epitopes, with CTL pres-
sure in patient SUMA being more evenly spread across a
greater number of epitopes during early infection than in
patients WEAU and BORI (Fig. 1). We also observed that
in all three patients, every epitope-specific CTL response
that had a particularly high relative immunodominance in
acute infection (comprising 25% of the overall T cell re-
sponse to the Env, Gag, and Tat epitopes identified in the
patient concerned) was escaped within 6-7 mo FOSx.
Subdominant responses directed against epitopes in Tat,
which likely also played a prominent role in in vivo control
of viral replication, were also rapidly escaped. Based on
these observations, we hypothesized that escape may be
promoted by biasing of CTL pressure toward particular
epitopes, and restricted by broad, codominant distribution
of CTL pressure; and correspondingly that qualitative fea-
tures of the HIV-specific CTL response may be important
determinants of the efficiency of control of viral replication
(perhaps more so than the magnitude of the response).
Consistent with this hypothesis, several studies have
found no relationship between the total magnitude of the
HIV-specific CD8 T cell response and the viral load at
different stages of infection (16, 33, 34). However, analyses
of substantial distortion of the T cell repertoire by mono/
oligoclonal T cell expansions during primary HIV infection
in patients who subsequently established high but not low
persisting viral loads (35, 36) support there being an associ-
ation between qualitative aspects of the primary HIV-spe-
cific T cell response and the efficiency of control of viral
replication, and further suggest that biasing of the response
toward immunodominant epitopes recognized by a limited
number of T cell clones may be detrimental. Interestingly,
two recent papers found no relationship between the num-
ber of epitopes recognized by the HIV-specific CD8 T
cell response and the viral load (16, 34). Neither paper
compared the breadth of the primary CD8 response with
the persisting viral load established in early infection; how-
ever, this observation could indicate that the relative im-
munodominance of epitope-specific responses (not reported
in these papers) is more critical in dictating the efficiency of
control of viral replication than the absolute number of
epitopes recognized, or that other factors have a dominant
influence on the efficiency of viral containment.
Another factor that likely has an important impact on the
extent and kinetics of viral escape from epitope-specific
CTL responses is the cost of escape to intrinsic viral fitness.
Although we did not perform any direct comparison of the
intrinsic fitness of viral isolates bearing index and mutant
epitope sequences, the impact of viral fitness costs on es-
cape was strongly suggested by comparison of the extent
and kinetics of escape from CTL responses directed against
epitopes in conserved versus more variable viral sequences.
Several other papers (22, 37) also provide examples of high
costs to intrinsic viral fitness restricting escape from CTL
responses to particular epitopes. Although our results sug-
gest that escape is less likely to occur if CTL pressure is
codominantly directed against multiple viral epitopes (i.e.,
if many epitopes are recognized, and both the relative im-
munodominance and the in vivo efficacy of all responses
are similar), selection for escape will also depend on the in-
terplay of these variables with costs of escape to intrinsic vi-
ral fitness. Thus, for example, a response biased against a
limited number of epitopes with very high escape-related
intrinsic fitness costs may be escaped to a lesser extent than
a broader response directed against epitopes where amino
acid change is readily accommodated. The complexity of
factors that interact to determine the extent and kinetics of
acute-phase CTL escape may mean that the persisting viral
load is not adequately reflected by consideration of any sin-
gle parameter in isolation.
If escape from an epitope-specific CTL response is pro-
moted as its contribution to overall control of viral replica-
tion increases, escape will be reduced not only as the
breadth and codominance of epitope-specific components
of the CTL response increases, but also as the contribution
made by other arms of the immune response (e.g., antibody
and CD4 T cell responses) to control of viral replication
increases. In support of this, studies in murine virus infec-
tion models have illustrated not only that CTL escape is
enhanced by biasing of T cell pressure toward a limited
number of viral epitopes (for review see reference 38), but
also that immune escape is promoted in situations where
one arm of the immune response makes a particularly over-
riding contribution to overall control of viral replication
(39). Interestingly, we were able to detect a strong HIV-
specific CD4 T cell response during primary infection in
patient SUMA but not in patients WEAU or BORI (40),
which may have helped to increase the breadth of the ef-
fector T cell response.
Our observation of CTL escape in patients who were
representative of individuals who naturally established per-
sisting viral loads in the uppermost and lowest ranges (10)
adds to a growing body of evidence suggesting that CTL
escape is prevalent in HIV-1 infection (9, 41, 42). If CTL
escape constitutes a common and significant means of im-
mune evasion in early HIV-1 infection, vaccination strate-
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gies should be designed to elicit a response that will have
the minimal chance of being escaped after infection. Our
findings indicate that one way in which escape can be re-
duced is by induction of a T cell response that exerts even
pressure against multiple viral epitopes (e.g., composed of
multiple epitope-specific responses of similar magnitude
and efficacy). Experience has already shown that efficacious
vaccine-induced CD8 T cell responses can be rapidly
evaded if they are too narrowly directed (43–45). How-
ever, our results further indicate that to reduce escape it
will also be important to induce CD8 T cell responses to
invariant sites in the virus, where escape is likely to be re-
stricted by costs to intrinsic viral fitness. Thus, we predict
that a CD8 T cell response-inducing vaccine is likely to
achieve optimal control of virus replication by eliciting
CTL responses of evenly high magnitude and efficacy to a
series of viral epitopes that exhibit high escape-related costs
to intrinsic viral fitness.
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